Anterior segment involvement in HIV-associated eye disease after the commencement of highly active antiretroviral therapy (HAART);Affektionen der vorderen augenabschnitte bei HIV-infektion nach einfuhrung der hochaktiven antiretroviralen therapie (HAART)

Klinische Monatsblatter fur Augenheilkunde

Volumn 216, Issue 2, 2000, Pages 61-67

  Garweg, Justus G ^a  

^a University Eye Clinic Bern   (Switzerland)

Author keywords

AIDS; Cidofovir ; CMV retinitis; Drug; Drug toxicity; Eye disease; HAART; HIV infection; HIV 1; Immune recovery uveitis; Induced disease; Rifabutin ; Vitreitis; VZV; Zoster dermatitis

Indexed keywords

ANTIRETROVIRUS AGENT; CIDOFOVIR; RIFABUTIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; STEROID;

ANTERIOR EYE SEGMENT; EYE DISEASE; EYE INFLAMMATION; EYE TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; UVEITIS; VITREOUS DISEASE; AIDS RELATED COMPLEX; CD4 LYMPHOCYTE COUNT; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; PARASITOLOGY; PATHOLOGY; RETINA DISEASE; RETINITIS; VIROLOGY; CELL INFILTRATION; CYTOMEGALOVIRUS INFECTION; EPIRETINAL MEMBRANE; INFLAMMATORY INFILTRATE; LYMPHOCYTE COUNT; POSTERIOR EYE CHAMBER; RETINA MACULA EDEMA; STEROID THERAPY; VIRUS LOAD; VISUAL IMPAIRMENT; VITREOUS BODY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; CYTOSINE; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EYE DISEASES; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RIFABUTIN; UVEITIS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS RETINITIS; RETINAL DISEASES;

EID: 0034010559     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-10519     Document Type: Review

References (62)

1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116
2. Boshoff C, Weiss RA. Kaposi's sarcoma-associated herpesvirus Adv Cancer Research 1998; 75: 57-86
3. Brockmeyer N, Barthel B. Clinical manifestations and therapies of AIDS associated tumors. Europ J Me Res 1998; 3: 127-47
4. Brun SC, Jakobiec FA. Kaposi's sarcoma of the ocular adnexa. Int Ophthalmol Clin 1997; 37: 25-38
5. Centers for Disease Control and Prevention. MMWR Morb Mortal Weekly Report 1997; 46: 165-173
6. Chang Y, Cesarman E, Pessin MS, Moore P, Lee F, Culpepper J et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869
7. Chavez-de la Paz E, Arevalo JF, Kirsch LS, Munguia D, Rahhal FM, De Clercq E et al. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirusretinitis. Analysis and prevention. Ophthalmology 1996; 104: 539-544
8. Connors M, Covacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Natural Medicine 1997; 3: 533-540
9. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/ 117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Diseases 1996; 174: 704-712
10. 10. Corey L, Holmes KK. Therapy for human immunodeficiency virus infection - what have we learned? New Engl J Med 1996; 335: 1142-1144
11. 11. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115: 733-737
12. Dugel PU, Gill PS, Frangieh GT, Rao N. Treatment of ocular adnexal Kaposi's sarcoma in acquired immunodeficiency syndrome. Ophthalmology 1992; 99: 1127-1132
13. Dugel PU, Rao NA. Ocular infections in the acquired immunodeficiency syndrome. Int Ophthalmol Clin 1993; 33: 103-127
14. Dunn JP. Immune recovery vitritis in HIV infection: abstracts and commentary. J Am Med Associat 1998; 280: 185-186
15. Engstrom RE Jr, Holland GN, Hardy WD, Meiselman HJ. Hemorheologic abnormalities in patients with human immunodeficiency virus infection and ophthalmic microvasculopathy. Am J Ophthalmol 1990; 109: 153-161
16. Fabricius EM, Prantl F, Jaeger H, Holzer E, Moller A, Greite JH. Zur Inzidenz und Pathogenese okularer Symptome bei HIV-Infektion. Fortschr Ophthalmol 1989; 86: 461-468
17. Franssen FF, Lumeij JT, van Knapen F. Susceptibility of Encephalitozoon cuniculi to several drugs in vitro. Antimicrobial Agents and Chemotherapy 1995; 39: 1265-1268
18. Garweg JG. Opportunistische Augenerkrankungen im Rahmen der HIV-Infektion. Klin Monatsbl Augenheilkd 1993; 202: 465-470
19. Garweg J, Böhnke M. Varicella-Zoster Virus is strongly associated with atypical necrotizing herpetic retinopathies. Clin Infect Dis 1997; 24: 603-608
20. Hemady RK. Microbial keratitis in patients infected with the human immunodeficiency virus. Ophthalmology 1995; 102: 1026-30
21. Henderson HW, Davidson F, Mitchell SM. Intraocular inflammation and the diffuse infiltrative lymphocytosis syndrome. Am J Ophthalmol 1998; 126: 462-464
22. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126
23. Hodge WG, Margolis TP. Herpes simplex virus keratitis among patients who are positive or negative for human immunodeficiency virus: an epidemic study. Ophthalmology 1997; 104: 120-124
24. Jabs DA, Green WR, Fox R, Polk BF, Barlett JG. Ocular manifestations of the acquired immunodeficiency syndrome. Ophthalmology 1989; 96: 1092-1098
25. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995; 93: 623-683
26. Jabs DA, Quinn TC. In: Pepose JS, Holland GN, Wilhelmus KR. Ocular Infection and Immunity. Mosby Year Book 1996; p. 289-310
27. Jabs DA, Bartlett JG. AIDS and ophthalmology: a period of transition. Am J Ophthalmol 1997; 124: 227-233
28. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443-1445
29. Jie C, Tulpule A, Zheng T, Masood R, Espina B, Gill PS. Treatment of epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol 1997; 9: 433-439
30. Jung C, Bogner JR, Goebel F. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy. Eur J Med Res 1998: 3: 439-442
31. Karavellas MP, Lowder CY, Macdonald C, Avila Jr CP, Freeman WR. Immune recovery vitreitis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998; 116: 169-175
32. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12: 45-49
33. Lucca JA, Farris RL, Bielory L, Caputo AR. Keratoconiunctivitis sicca in male patients infected with the human immunodeficiency virus type 1. Ophthalmology 1990; 97: 1008-1010
34. Lucht E, Brytting M, Bjerregaard L, Julander I, Linde A. Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. Clin Infect Dis 1998; 27: 137-141
35. Maclean H, Dhillon B, Ironside J. Squammous cell carcinoma of the eyelid and the acquired immunodeficiency syndrome. Am J Ophthalmol 1996; 121: 219-221
36. McGarvey ME, Tulpule A, Cae J, Zeng T, Masood R, Espina B et al. Emerging treatment for epidemic (AIDS related) Kaposi's sarcoma. Curr Opin Oncol 1998; 10: 413-421
37. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170
38. Molina JM, Chastang C, Goguel J, Michiels JF, Sarfati C, Desportes-Livage I et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1992; 177: 1373-1377
39. Moore P, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995; 332: 1181-1185
40. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol 1996; 70: 549-558
41. Nicholas J, Zong JC, Alcendor DJ, Ciufo DM, Poole LJ, Sarisky R et al. HIV: Changing pattern of io inflammation. Am J Ophthalmol 1998: 128: 374-382
42. Pepose JS, Holland GN, Nestor MS et al. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology 1985; 92: 472-484
43. Purtilo DT. Oportunistic cancers in patients with immunodeficiency syndroms. Arch Pathol Lab Med 1987; 111: 1123-1129
44. 44. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997; 124: 199-205
45. Regamey N, Cathomas G, Schwager M, Wernli M, Harr T, Erb P. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol 1998; 36: 1784-1786
46. Reitz MS, Hayward GS, Nicholas J, Zong JC, Alcendor DJ, Ciufo DM et al. Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. J Nat Cancer Inst. Monographs 1998; 23: 79-88
47. Sanislo SR, Lowder CY, Kaiser PK. Optic nerve head neovascularization in a patient with inactive cytomegalovirus retinitis and immune recovery. Am J Ophthalmol 1998; 126: 318-320
48. Saran BR, Maguire AM, Nichols C, Frank I, Hertle RW, Brucker AJ et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994; 112: 1159-1165
49. Shafran S, Deschenes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med 1994; 330: 438-439
50. Shuler JD, Holland GN, Miles SA, Miller BJ, Grossman I. Kaposi sarcoma of the conjunctiva and eyelids associated with the acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 858-862
51. Shuler J, Engstrom RR Jr., Holland GN. External ocular disease and anterior segment disorders associated with AIDS. Int Ophthalmol Clin 1989; 29: 98-104
52. Spina M, Gaidano G, Carbone A, Capello D, Tirelli U. Highly active antiretroviral therapy in human herpesvirus-8-related body-cavity-based lymphoma. AIDS 1998; 12: 955-956
53. Stephenson J. The art of "HAART": researchers probe the potential and limits of aggressive HIV treatments. J Am Med Associat 1997; 277: 614-616
54. Taskintuna I, Rahhal FM, Arevalo JF, Munguia D, Banker AS, De Clercq E et al. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1997; 104: 1049-1057
55. Teich SA. Conjunctival vascular changes in AIDS and AIDS-related complex. Am J Ophthalmol 1987; 103: 332-333
56. Tulpule A, Matheny SC. AIDS-Related malignancies. Primary Care 1998: 25: 473-482
57. Turner BJ, Hecht FM, Ismail RB. CD4+ T-lymphocyte measures in the treatment of individuals infected with human immunodeficiency virus type 1. A review for clinical practitioners. Arch Int Med 1994; 54: 1561-1573
58. Vrabec TC, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998; 105: 1259-64
59. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99: 1739-1750
60. Whitcup SM, Fortin E, Nussenblatt RB, Polis MA, Muccioli C, Belfort R Jr. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. J Am Med Associat 1997; 277: 1519-1520
61. WHO. UnAIDS. WHO-Report December '97
62. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998; 39: 741-745